This biotech specializes in small molecule kinase inhibitors for cancer, with lead drug candidates in early-stage clinical ...

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

Kyle Diamantas, the acting commissioner of the FDA, is expected to be a drama-free, stabilizing caretaker at the top of the ...

In a letter to President Donald Trump, a group of biotech executives recommended former cancer regulator Richard Pazdur to ...

Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting ...

PDS Biotechnology (NASDAQ:PDSB) reported a smaller first-quarter loss and highlighted changes to its late-stage head and neck ...

Biotech dealmaking accelerated heading into the JPM 2026 Healthcare Conference as large drugmakers face looming patent cliffs ...

Inovio Pharmaceuticals and Novavax stocks pare back earlier gains as the rally loses enthusiasm. Following a robust rally, Moderna appears to be regaining leadership within the biotech space. This ...

Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, ...

On May 7, Genmab A/S (NASDAQ:GMAB) reported revenue of $896 million for Q1 2026, rising 25% from $715 million a year earlier.

Quick Read NeOnc and Plus Therapeutics operate in the same CNS oncology space as CNS Pharmaceuticals but carry deeper ...

Discover the role of biotechnology in healthcare, medicine, and investment. Understand biotech processes, top companies, and ...